These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8100697)

  • 1. Can women with gonadotropin levels diagnostic of polycystic ovarian syndrome benefit from therapy with dopamine agonists?
    Harrison RF; Synnott M; O'Moore R; O'Moore M
    Ann N Y Acad Sci; 1993 May; 687():272-9. PubMed ID: 8100697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine might not be involved in the pathogenesis of polycystic ovary syndrome.
    Ferriani RA; Silva de Sá MF; Moura MD; Moreira AC; Gomes UA
    Gynecol Endocrinol; 1989 Dec; 3(4):317-27. PubMed ID: 2516707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrinological environment of polycystic ovarian disease.
    Tanaka T; Fujimoto S
    Horm Res; 1990; 33 Suppl 2():5-9. PubMed ID: 2128882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycystic ovary syndrome or hyperprolactinaemia: a study of mild hyperprolactinaemia.
    Su HW; Chen CM; Chou SY; Liang SJ; Hsu CS; Hsu MI
    Gynecol Endocrinol; 2011 Jan; 27(1):55-62. PubMed ID: 20504100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistant cases of polycystic ovarian disease successfully treated with a combination of corticosteroids, clomiphene, and bromocriptine.
    Homburg R; Ashkenazi J; Goldman J
    Int J Fertil; 1988; 33(6):393-7. PubMed ID: 2906913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metoclopramide effect on serum prolactin LH and FSH in patients with polycystic ovary syndrome.
    Prelević GM; Würzburger MI; Perić LA
    J Endocrinol Invest; 1988 Apr; 11(4):255-9. PubMed ID: 3137253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The hyperprolactinemic polycystic ovary syndrome may not be an distinct entity.
    Corenblum B; Taylor PJ
    Fertil Steril; 1982 Nov; 38(5):549-52. PubMed ID: 6813147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous administration of pulsatile gonadotropin-releasing hormone decreases serum follicle-stimulating hormone and luteinizing hormone levels in women with polycystic ovary syndrome: a preliminary study.
    Graña-Barcia M; Liz-Lestón J; Lado-Abeal J
    Fertil Steril; 2005 May; 83(5):1466-72. PubMed ID: 15866586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperprolactinemia in polycystic ovary syndrome.
    Luciano AA; Chapler FK; Sherman BM
    Fertil Steril; 1984 May; 41(5):719-25. PubMed ID: 6425087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian age-related responsiveness to human chorionic gonadotropin in women with polycystic ovary syndrome.
    Piltonen T; Koivunen R; Perheentupa A; Morin-Papunen L; Ruokonen A; Tapanainen JS
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3769-75. PubMed ID: 15292303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute effects of L-dopa and bromocriptine on serum PRL, LH and FSH levels in patients with hyperprolactinemic and normoprolactinemic polycystic ovary syndrome.
    Prelević GM; Würzburger MI; Perić LA
    J Endocrinol Invest; 1987 Aug; 10(4):389-95. PubMed ID: 3119696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
    Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
    Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
    Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Women with oligo-/amenorrhoea and polycystic ovaries have identical responses to GnRH stimulation regardless of their androgen status: comparison of the Rotterdam and Androgen Excess Society diagnostic criteria.
    Lewandowski KC; Cajdler-Luba A; Bieńkiewicz M; Lewiński A
    Neuro Endocrinol Lett; 2011; 32(6):847-56. PubMed ID: 22286802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of dopaminergic activity of the hypothalamus in patients with polycystic ovarian syndrome].
    Zironi C; Pantaleoni M; Zizzo G; Coletta F; Velardo A
    Minerva Ginecol; 1991 Oct; 43(10):443-7. PubMed ID: 1685015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy predictors for metformin and clomiphene citrate treatment in anovulatory infertile patients with polycystic ovary syndrome.
    Palomba S; Falbo A; Orio F; Tolino A; Zullo F
    Fertil Steril; 2009 Jun; 91(6):2557-67. PubMed ID: 18440534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of basal luteinizing hormone:follicle-stimulating hormone ratio in the treatment of patients with polycystic ovarian syndrome by assisted reproduction techniques.
    Tarlatzis BC; Grimbizis G; Pournaropoulos F; Bontis J; Lagos S; Spanos E; Mantalenakis S
    Hum Reprod; 1995 Oct; 10(10):2545-9. PubMed ID: 8567767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naloxone does not interfere with the dopamine-induced decrease in gonadotropin secretion in women with polycystic ovarian disease.
    Paradisi R; Margrini O; Venturoli S; Fabbri R; Porcu E; Stanzani L; Flamigni C
    Horm Metab Res; 1985 Jan; 17(1):29-31. PubMed ID: 3917966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Mullerian Hormone: an indicator for the severity of polycystic ovarian syndrome.
    Köninger A; Koch L; Edimiris P; Enekwe A; Nagarajah J; Kasimir-Bauer S; Kimmig R; Strowitzki T; Schmidt B
    Arch Gynecol Obstet; 2014 Nov; 290(5):1023-30. PubMed ID: 24961320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.